Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
With
University of Washington
Denver Health Medical Center
Children's Hospital Medical Center, Cincinnati
Patients with end stage liver disease that receive a liver transplant will be studied to determine if novel serum and urine biomarkers (serum cystatin C, urine interleukin-18 \[IL-18\] and urine neutrophil gelatinase associated lipocalin \[NGAL\]) can predict the outcome measures listed above.
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
First time liver transplant recipient
Cadaveric or living donor livers
You may not be if
Unconscious patients or patients who cannot give consent
Pregnant women
Prisoners
Patients receiving dialysis before or during liver transplant operation
